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Introduction
Pancreatic exocrine tumors make up approximately 95% 
of  pancreatic malignancies. Those of  acinar cell differen-
tiation are the least common, making up 1-2% of  exocrine 
pancreatic neoplasms; neuroendocrine tumors (NET) are 
much more common (1). There have been many reports of  
neuroendocrine components within pancreatic acinar cell 
carcinomas (ACC) with varying percentages of  neuroendo-
crine cells and a variety of  neuroendocrine cell subtypes. In 
2010, the World Health Organization (WHO) defined a 
mixed adenoneuroendocrine carcinoma (MANEC) as a 
neoplasm containing at least 30% of  both acinar and neu-
roendocrine cells (2). While approximately 40% of  pancre-
atic ACC contain neuroendocrine cells, fewer than 30 cases 
of  MANEC with pancreatic acinar differentiation have 
been reported in the literature (3). Malignant transforma-
tion within ectopic pancreatic tissue is also exceedingly 
rare, with fewer than 15 cases reported in the literature (4).
Case report
A 65-year-old male with a past medical history of  peptic 
ulcer disease presented to the emergency department with 
complaints of  nausea, vomiting, frequent watery melanotic 
stools, tremors, and right-upper-quadrant abdominal pain 
of  approximately 1 week's duration. Pertinent negatives 
included no history of  liver dysfunction, malignancy, diabe-
tes, arthralgias, or skin rashes.
The patient had stable vital signs and was in no acute 
distress. There were hyperactive bowel sounds, and the 
patient's epigastrium was tender to palpation without re-
bound tenderness or peritoneal signs. 
The patient had a normal WBC of  9.5 x109/L (normal 
range: 4.4- 11.3 x109/L) as well as lipase of  19 U/L (nor-
mal range: 13 – 60 U/L). Outside of  a slight elevation of  
LDH to 230 (normal range: 135 - 225 U/L), the patient’s 
hepatic panel was unremarkable, with albumin 3.8 g/dL 
(normal range: 3.5 – 5.2 g/dL), AST 26 U/L (normal 
range: 0 – 40 U/L), ALT 14 U/L (normal range: 0 – 41 
U/L),  alkaline phosphatase 118 (normal range: 40 – 129 
U/L), and total bilirubin 0.7 mg/dL (normal range: 0.1 – 
1.2 mg/dL). 
Abdominal radiographs demonstrated a mass in the up-
per abdomen with mass effect on the surrounding bowel 
(Fig. 1). A subsequent CT of  the abdomen and pelvis, en-
hanced with intravenous and oral contrast and imaged 
during the portal venous phase, revealed a lobulated 13.5 x 
11.8 x 10.5-cm, heterogeneously enhancing mass in the left 
hepatic lobe, with central hypoattenuating material thought 
to represent necrosis (Fig. 2). There was no imaging evi-
dence of  cirrhosis or portal hypertension. Outside of  a 
7mm hypodensity in the pancreatic head, the pancreas was 
unremarkable, with no suspicious mass (Fig. 3). 
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Additional laboratory workup after admission included a 
hepatitis panel that showed a positive hepatitis B virus core 
antibody (HBcAb). The patient’s serum alpha-fetoprotein 
level (AFP) was within normal limits at 2.55 ng/mL (nor-
mal range: 0-8.30 ng/mL).  
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Figure 3. 65-year-old male with pancreatic differentiated 
MANEC within the left hepatic lobe. Axial T1 (A) and T2 (B) 
weighted images show a large lobulated tumor in the left 
hepatic lobe with a T1- hypointense, T2-hyperintense scar 
(open arrow) with multiple surrounding simple cysts (stars) 
and intratumoral foci of hemorrhage at the periphery. 
Figure 2. 65-year-old male with pancreatic differentiated MANEC within the left he-
patic lobe. Axial (A) and coronal (B) CT images of the abdomen show a 13.5 x 11.8 x 
10.5-cm, heterogeneously enhancing mass in the left hepatic lobe with central hypo-
density (open arrow). No calcifications or satellite lesions are seen. Incidental simple 
hepatic cysts are nearby.
Figure 1. 65-year-old male with pan-
creatic differentiated MANEC within 
the left hepatic lobe. Frontal radio-
graph of the abdomen demonstrates 
a large opacity (open arrows) in the 
right upper quadrant with mass effect 
on the adjacent air-filled bowel and 
stomach. 
Figure 4. 65-year-
old male with pan-
creatic differenti-
ated MANEC 
within the left he-
patic lobe. Axial 
diffusion-weighted 
imaging (A) dem-
onstrates high 
signal throughout 
the tumor. The 
corresponding 
ADC  sequence 
(B) shows high 
signal intensity 
within the central 
scar due to T2 
“shine-through” 
and confirms re-
stricted diffusion in 
the surrounding 
tumor paren-
chyma.
Further evaluation with a gadolinium-enhanced MRI of  
the abdomen, using the hepatocyte-specific contrast agent 
gadobenate dimeglumine, demonstrated an isointense mass 
on T1 and T2 sequences, with a T2-hyperintense central 
scar (Fig. 4). The tumor was heterogeneously hyperenhanc-
ing in the arterial phase, with relative washout in the portal 
venous phase. A central scar was noted that demonstrated 
progressive accumulation of  the gadolinium-based contrast 
agent (GBCA) on 10-minute delayed and hepatobiliary (60-
minute) phases (Figs. 5, 6).  
No solid mass was seen in the pancreas on MRI. The 
7mm pancreatic head hypodense lesion was shown to be 
cystic without internal septation, or nodularity. While le-
sions this small are difficult to characterize, statistically this 
would most likely represent a benign intrapancreatic muci-
nous neoplasm and is unrelated to the liver mass. 18 
months of  subsequent followup has not shown any change 
in this cystic lesion.  
There were multiple simple cysts, with no other suspi-
cious liver lesions identified. There were no signs of  cirrho-
sis and no evidence of  metastatic spread to lymph nodes or 
other organs. 
Based on the MRI findings, a biopsy of  the liver mass 
was recommended for further evaluation. Ultrasound-
guided biopsy of  the liver produced initial pathology results  
consistent with a low-grade (well differentiated) neuroendo-
crine tumor (NET) with negative hepatic markers. 
A 24-hour urine specimen showed normal 5-
Hydroxyindoleacetate (5-HIAA) of  3.9 mg/24 hrs. (nor-
mal: 6.0 mg/24 hrs. or less). The surgical oncologist re-
quested an indium-111 pentreotide (Octreoscan) test be-
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Figure 5. 65-year-old male with pancreatic differentiated MANEC within the left hepatic lobe. Contrast-enhanced axial LAVA 
FS images during the arterial phase (A), at 5 min (B), and at 10 min (C) demonstrate arterial enhancement of the MANEC 
followed by slight washout relative to the liver. The central scar demonstrates delayed enhancement (C).
Figure 6. 65-year-old male with pancreatic differentiated 
MANEC within the left hepatic lobe. Contrast-enhanced 
coronal LAVA FS image at 60 minutes (hepatobiliary phase) 
demonstrates no retention of the hepatobiliary agent in the 
tumor parenchyma. Progressive enhancement of the cen-
tral scar is seen, but not due to biliary excretion of the hepa-
tobiliary agent; rather, the dense cellular matrix of the scar 
traps the gadolinium chelate.
Figure 7. 65-year-old male with pancreatic differentiated 
MANEC within the left hepatic lobe. Whole-body planar 
images 24 hours after the administration of 5.98 mCi of 
indium-111 demonstrate physiologic uptake within the liver, 
spleen, kidneys, and bowel with no evidence of radiotracer 
uptake within the hepatic tumor.     
cause the origin of  the neuroendocrine tumor was not 
clear, based on imaging and biopsy. This study revealed no 
tracer uptake in the hepatic mass, pancreas, bowel, or else-
where in the body (Fig. 7). The patient proceeded to left 
hepatic lobectomy, with specimens sent to two separate 
tertiary referral centers for consultation (see Fig. 8 for gross 
specimen). Additional immunohistochemical stains demon-
strated a moderately poorly differentiated carcinoma with 
mixed neuroendocrine and acinar cell differentiation, with 
stronger chromogranin consistent with predominant neuro-
endocrine differentiation (Fig. 9). The final pathology diag-
nosis was MANEC, with the report suggesting that the 
most likely source as metastasis from the pancreas or (less 
likely) ectopic pancreatic tissue in the liver. However, fol-
lowup imaging over 14 months has demonstrated no evi-
dence of  recurrent disease, nor has a primary pancreatic 
mass manifested itself, leading us to conclude that the tu-
mor did indeed arise from ectopic pancreatic tissue in the 
liver.
Discussion
Patients with MANEC of  the pancreas tend to be 
middle-aged and present with nonspecific symptoms, com-
monly vague abdominal pain (5). Due to the propensity of  
this tumor to arise in the pancreatic head, as well as its 
larger size, other symptoms can include nausea, vomiting, 
weight loss, and jaundice. While MANECs contain neuro-
endocrine cells, the vast majority of  these tumors are non-
hyperfunctioning or nonsyndromic, suggesting that these 
cells remain in a primitive state or produce immature hor-
mones (1). That being said, there are case reports of  hyper-
functioning MANECs presenting with symptoms of  watery 
diarrhea, similar to this case, as well as Zollinger-Ellison 
Syndrome (6, 7). A subset of  pure ACC develops a lipase 
hypersecretion syndrome characterized by skin rashes, ar-
thralgias, and fat necrosis. 
Reported MANECs in the pancreas have been large 
(>7cm), and are most commonly found in the pancreatic 
head. Additionally, as demonstrated in this case, a MANEC 
can arise in other organs with no evidence of  pancreatic 
involvement. Review of  the literature illustrated 5 cases 
arising from the stomach (8-10). It is theorized that pancre-
atic metaplasia or ectopic pancreatic tissue may account for 
these extrapancreatic MANECs. Metastatic disease has 
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Figure 8. 65-year-
old male with pan-
creatic differenti-
ated MANEC 
within the left he-
patic lobe. (A) The 
large lobulated 
tumor within the 
left hepatic lobe, 
status post lobec-
tomy. (B) The 
transected tumor 
with a central stel-
late scar.
Figure 9. 65-year-old male with pancreatic differentiated 
MANEC within the left hepatic lobe. Immunohistochemical 
stains of the MANEC demonstrate weak, diffuse staining 
with chromogranin (A) and patchy staining with synapto-
physin (B), both of which are neuroendocrine markers. The 
WHO requirement for the diagnosis of MANEC requires at 
least 30% acinar and neuroendocrine differentiation. 
been reported both in tumors arising from the pancreas 
as well from in those originating in other organs. 
To our knowledge, only one paper has been dedicated to 
describing the imaging findings of  a MANEC (11). In that 
case, CT demonstrated a heterogeneous, hypoattenuating, 
8 x 2.5-cm mass within the pancreatic tail with capsule-like 
enhancement. On MRI, the mass was T2-heterogeneously 
hyperintense with a T2-hypointense nodular focus. The 
tumor demonstrated heterogenous enhancement, with 
more diffuse enhancement in the previously described 
nodule. Given the limited number of  cases in the literature, 
there are no classic imaging findings for this particular tu-
mor, and previous studies have combined MANEC with 
pure ACC in analyses.  
With such little information available, it is worthwhile to 
describe the appearance of  pancreatic ACC, as the acinar 
component may result in similar imaging features. These 
tumors are often found in the pancreatic head and tend to 
be large at presentation with a mean diameter of  7.1 cm 
(12). Presenting symptoms may include arthralgias, skin 
rashes, and fat necrosis from lipase hypersecretion. Larger 
ACCs tend to develop cystic areas centrally, likely related to 
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Condition Seen on CT Seen on MRIFibrolamellar	  HCC *	  Large,	  well	  circumscribed	  mass	  with	  hy-­‐podense	  central	  scar	  (70%)*	  Heterogeneously	  arterial	  enhancement*	  Scar	  may	  show	  late	  enhancement	  (10-­‐15	  min)
*	  Heterogeneous	  arterial	  enhancement	  of	  the	  mass
FNH * Hypodense	  to	  isodense	  mass*	  	  50%	  contain	  a	  central	  scar*	  	  Homogeneous	  arterial	  enhancement	  that	  fades	  away,	  becomine	  isodense	  to	  normal	  liver*	  	  Scar	  demonstrates	  delayed	  enhance-­‐ment	  (3-­‐5	  min)
* Iso-­‐	  to	  hypo-­‐isointense	  on	  T1,	  mildly	  hyper-­‐isointense	  on	  T2,	  with	  T2	  bright	  central	  scar*	  	  Arterial	  phase	  homogeneous	  enhancement	  of	  the	  tumor	  with	  lack	  of	  scar	  enhancement.	  Tumor	  gradually	  decreases	  to	  liver	  intensity	  while	  the	  scar	  enhances	  in	  delayed/hepatobiliary	  phases.*	  	  Hepatobiliary	  phase	  rentention	  of	  contrast	  is	  nearly	  diagnosticHCC *	  NECT:	  Hypodense	  mass,	  may	  develop	  central	  necrosis*	  Arterial	  enhancement	  with	  portal	  venous	  washout*	  Larger	  masses	  may	  have	  necrotic	  areas	  or	  vascular	  invasion
* Variable	  T1	  signal,	  T2	  iso-­‐	  to	  hyperintense*	  Arterial	  enhancement	  with	  delayed	  washout
Cavernous	  he-­‐mangioma *	  Hypodense	  mass,	  may	  appear	  hetero-­‐genseous	  with	  central	  scar	  when	  large*	  Peripheral	  nodular	  enhancement	  with	  progressive	  centripetal	  Sill-­‐in
* Hypointense	  on	  T1,	  hyperintense	  on	  T1*	  	  Hepatocyte-­‐speciSic	  contrast	  agent	  will	  mirror	  the	  blood	  vessels,	  and	  at	  time	  show	  "pseudo-­‐washout"	  in	  the	  equilibrium	  phase	  due	  to	  rapid	  uptake	  by	  the	  liverHepatic	  metasta-­‐ses * Multifocal*	  	  Central	  scar	  has	  been	  reported	  on	  some	  larger	  metastases,	  but	  necrosis	  is	  much	  more	  common
*	  High	  T2	  signal	  intensity
MANEC * Large,	  heterogeneously	  enhancing	  mass	  with	  central	  necrosis*	  	  Look	  for	  pancreatic	  primary	  mass * Isointense	  on	  T1	  and	  T2*	  	  T2-­‐hyperintense	  central	  scar*	  	  Early	  arterial	  enhancement	  and	  washout	  in	  the	  portal	  venous	  phase	  with	  retention	  in	  the	  central	  scar
Table. Differential diagnosis for a hepatic tumor with a central scar
necrosis. The most common enhancement pattern reported 
tends to be hypovascular relative to the pancreas and ho-
mogeneous. ACC in the pancreas has not been described 
with a central scar. Calcification is reported in a small mi-
nority of  pancreatic ACCs (6%). Hepatic metastases from 
ACC tend to be lobulated and well defined, and enhance 
less than hepatic parenchyma. 
Given the rarity of  this diagnosis, one of  the greatest 
utilities of  discussing this case is generating a differential for 
this mass and highlighting why it does not fit the classic 
pattern for more prevalent diagnoses. One of  the more 
notable findings to base a differential on was the central 
scar within the mass. The classic differential for a hepatic 
mass with a central scar includes, among many others (Ta-
ble), fibrolamellar HCC and focal nodular hyperplasia 
(FNH). Fibrolamellar HCC is ordinarily seen in young 
adults with noncirrhotic livers. These masses present as 
large, well-circumscribed hepatic tumors with a hypodense 
central scar. Unlike the case presented, the true central scar 
of  fibrolamellar HCC appears hypointense on both T1 and 
T2 sequences; only a small subset demonstrate delayed 
enhancement of  the scar. This is in contradistinction to 
FNH, in which the central “scar” is actually an aggregate of 
vessels and bile ducts (13). On NECT, an FNH scar appears 
hypoattenuating to isodense to liver. On MRI, it is gener-
ally hypointense to isointense on T1, and slightly hyperin-
tense on T2 with a bright central scar, similar to the MA-
NEC presented here (14). Multiphase MRI evaluation 
shows homogeneous arterial enhancement of  a well-
defined, lobulated tumor with initial hypointensity of  the 
central scar. On delayed phases, the tumor will fade in sig-
nal intensity to approach that of  the background liver, 
while the central “scar” will gradually enhance until hyper-
intense delayed phases. The retention of  contrast in the 
tumor parenchyma in FNH distinguishes it from tumors 
without functional hepatocytes and from the MANEC, 
which did not retain the hepatobiliary agent in the tumor 
parenchyma during the hepatobiliary phase. 
The behavior of  the central scar in this case was interest-
ing and represented a potential pitfall on the 60-minute 
delayed hepatobiliary phase. Though exceptions exist, re-
tention of  hepatobiliary specific contrast agents in tumor 
parenchyma at hepatobiliary phase suggests functioning 
hepatocytes (15). However, this lesion had no retention in 
the tumor parenchyma. The accumulation in scars is a 
typical feature of  all GBCA, and this trapping of  contrast is 
an essential tool in cardiac MRI, resulting from a reduced 
ability of  the scar tissue to clear the gadolinium deposited 
there.    
At initial presentation, hepatocellular carcinoma (HCC) 
was a legitimate concern in the setting of  a single hepatic 
lesion and no other suspicious abdominal masses. With no 
indicators of  active infection, the patient’s positive hepatitis 
B core antibody was likely an indicator of  resolved infec-
tion or a false positive test. While there are cases of  HCC 
documented in patients with noncirrhotic livers and 
HBcAb and surface antibodies, in general the hepatitis B 
replication rate is low or absent in the setting of  isolated 
HBcAb, and the risk of  HCC is low (16, 17). In noncir-
rhotic livers, HCC can present as large masses with central 
necrosis. On contrast-enhanced CT (CECT), they usually 
enhance heterogeneously in the arterial phase, with wash-
out in the portal venous phase. MRI features include vari-
able T1 signal, mild T2 hyperintensity, and heterogenous 
arterial phase enhancement, with subsequent washout in 
the remaining phases. These characteristic findings are not 
consistent with the MANEC reported, which was isointense 
on T1 and T2, diffusely enhancing, and exhibited delayed 
scar enhancement. There are cases where moderate- to 
well-differentiated HCCs can retain some capacity in han-
dling bile and infrequently retain gadobenate dimeglumine 
in the parenchyma during the hepatobiliary phase (18).  
Cavernous hemangiomas are the most common benign 
primary hepatic tumors. Given the large size of  the case 
reported, a giant cavernous hemangioma might have been 
a consideration. On NECT, they appear heterogeneous 
and (when large) can occasionally contain a central hypoat-
tenuating scar. However, CECT would show peripheral 
nodular enhancement in the arterial phase, with progres-
sive centripetal enhancement in the venous and delayed 
phases. Cavernous hemangiomas are hypointense on T1 
and markedly hyperintense on T2. If  a central scar is pre-
sent, it will not demonstrate enhancement (20). Extracellu-
lar contrast agents usually demonstrate similar features to 
CECT, while hepatocyte-specific contrast agents will mir-
ror the blood vessels and at times show "pseudo washout" 
in the equilibrium phase due to rapid uptake by the liver 
(19).
Early pathologic reports from the biopsy of  the MANEC 
suggested a well-differentiated NET. The negative hepatic 
markers were not consistent with a primary hepatic NET 
(also known as primary hepatic carcinoid), another very 
rare tumor. Primary hepatic NETs appear variable on T2 
and hypointense on T1, and demonstrate heterogeneous 
enhancement in the arterial phase with washout in the por-
tal venous phase. There are reports of  contrast accumula-
tion in central scars of  hepatic NETs during the equilib-
rium phase; however, no data was found on the hepatobili-
ary phase (20). Liver metastases are commonly seen with 
pancreatic or small-bowel NETs. On MRI, these lesions 
are hypointense on T1 and hyperintense on T2. They are 
known for being hypervascular and demonstrate early, in-
tense, homogeneous enhancement or occasionally periph-
eral rim enhancement, with progressive fill-in on delayed 
images (21). The lack of  In-111 on the Octreoscan, while 
not definitive alone, provided molecular imaging evidence 
against a NET diagnosis. 
To summarize the comparison to these primary hepatic 
tumors, the presence of  a scar and a noncirrhotic liver 
made HCC very unlikely. While the overall appearance 
was most similar to FLHCC, the T2 hyperintensity of  the 
scar and patient age did not fit. The size, foci of  necrosis, 
and lack of  functional hepatocytes as shown on the hepa-
tobiliary phase excluded FNH. The enhancement pattern 
of  this mass did not parallel the blood pool to support a 
cavernous hemangioma, and the central scar in a heman-
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gioma would not enhance. A primary hepatic NET is an-
other rare consideration; however, imaging findings to in-
clude nuclear medicine studies did demonstrate classic 
features. 
Surgery is the treatment of  choice if  a MANEC is re-
sectable; however, there is no large-scale followup data for 
alternatives such as tumor debulking or antiproliferative 
therapy. A review examined the first eleven pancreatic 
MANECs and found that four patients died from 5 to 24 
months after diagnosis, while six were disease-free 4 to 72 
months after the initial diagnosis (21). In this case, followup 
imaging has demonstrated no evidence of  recurrent or re-
sidual disease for over 18 months. 
Conclusion
Pancreatic MANEC is a rare neoplasm that can be dis-
covered as an isolated finding in organs other than the pan-
creas, with radiological features that can mimic more 
common tumors. Multiphase MRI can help further narrow 
the differential and exclude other more prevalent tumors.
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